MOLBIO · Hospital & Healthcare Services
Molbio Diagnostics reported revenue of ₹399 cr for April to June 2026, +320.0% on the year and −9.1% on the quarter.
Operating profit (EBITDA) was ₹92.0 cr, a margin of 23.1%, +3,358 bps on the year and −132 bps on the quarter.
The company swung to a net profit of ₹57.0 cr from a loss of ₹13.0 cr a year earlier, with earnings per share of ₹5.02.
A hospital chain grows by filling beds and lifting revenue per bed. New hospitals dilute margins in their first years, so a margin dip during expansion is not on its own a sign of weakness. The quarterly statements do not carry occupancy, revenue per occupied bed and new beds added; those come with the filing read.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Turned profitable from a loss a year ago.
Source: Quarterly statements
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
FinMinutes scored the offer document 63/100 before listing. 0 quarters of numbers since. Promise against delivery
| Q1 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|
| Revenue | ₹95.0 cr | ₹439 cr | ₹399 cr |
| YoY | — | — | +320% |
| EBITDA margin | −10.5% | 24.4% | 23.1% |
| Other income, % of PBT | — | 3% | 1% |
| Exceptional items | — | — | — |
| Tax rate | — | 28% | 25% |
| Net profit | −₹13.0 cr | ₹66.0 cr | ₹57.0 cr |
| YoY | — | — | — |
| Core profit YoY | — | — | — |
| EPS | −₹5.95 | ₹5.83 | ₹5.02 |
| Flags | · | · | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Molbio Diagnostics reported revenue of ₹399 cr (+320.0% on the year) and net profit of ₹57.0 cr (— on the year) for April to June 2026.
None of the 6 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.